Translate

Τετάρτη 29 Μαΐου 2019

Adalimumab-Related Dental Implant Infection
Joseph E. Cillo Jr., DMD, MPH, PhD ∗,∗,'Correspondence information about the author DMD, MPH, PhD Joseph E. CilloEmail the author DMD, MPH, PhD Joseph E. Cillo, Nicholaus Barbosa, DMD, MD †
PlumX Metrics
DOI: https://doi.org/10.1016/j.joms.2019.01.033 |
showArticle Info
Abstract
Full Text
Images
References
We present an adalimumab-related dental implant surgical-site infection. A 55-year-old patient with a history of twice-weekly adalimumab subcutaneous injections for ulcerative colitis underwent mandibular extractions and placement of 5 immediate dental implants. She experienced intraoral purulent drainage from all 5 dental implant sites with submental and submandibular space infections 2 weeks after surgery. Treatment consisted of extraoral incision and drainage of involved fascial spaces, removal of all mandibular dental implants, and debridement of necrotic mandibular bone. She went on to heal uneventfully. In individuals taking adalimumab, severe infection with loss of implants and bone may develop.

Adalimumab, sold under the brand name Humira among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis. Wikipedia

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αρχειοθήκη ιστολογίου

Translate